Abstract
Multiple factors make adherence to antiretroviral therapy (ART) a complex process. This study aims to describe the barriers and facilitators to adherence for patients receiving first-line and second-line ART, identify different adherence strategies utilized and make recommendations for an improved adherence strategy.
This mixed method parallel convergent study will be conducted in seven high volume public health facilities in Gauteng and one in Limpopo province in South Africa. The study consists of four phases; a retrospective secondary data analysis of a large cohort of patients on ART (using TIER.Net, an ART patient and data management system for recording and monitoring patients on ART and tuberculosis (TB) from seven Johannesburg inner-city public health facilities (Gauteng province); a secondary data analysis of the Intensified Treatment Monitoring Accumulation (ITREMA) trial (a randomized control trial which ran from June 2015 to January 2019) conducted at the Ndlovu Medical Center (Limpopo province); in-depth interviews with HIV infected patients on ART (in both urban and rural settings); and a systematic review of the impact of treatment adherence interventions for chronic conditions in sub-Saharan Africa. Data will be collected on demographics, socio-economic status, treatment support, retention in care status, disclosure, stigma, clinical markers (CD4 count and viral load), self-reported adherence information, intrapersonal, and interpersonal factors, community networks, and policy level factors. The systematic review will follow the PRISMA reporting and PICO criteria. Analyses will involve tests of association (Chi-square and t-test), thematic analysis (deductive and inductive approaches) and network meta-analysis.
Using an integrated multilevel socio-ecological framework this study will describe the factors associated with adherence for HIV infected patients who are taking first-line or second-line ART. Implementing evidence-based adherence approaches, when taken up, will improve patient’s overall health outcomes. Our study results will provide guidance regarding context-specific intervention strategies to improve ART adherence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The principal investigator/SBG is funded by the Utrecht University (UU), Department of Interdisciplinary Social Science, Netherlands (https://www.uu.nl/en/organisation/faculty-of-social-and-behavioural-sciences), and by the Carnegie Corporation of New York (www.carnegie.org/) (Grant No--B 8606.R02), Sida (www.sida.se/en) (Grant No:54100113), the DELTAS Africa Initiative (www.aasciences.africa/aesa/programmes/developing-excellence-leadership-training-and-science-africa-deltas-africa#) (Grant No: 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD) (www.daad.de/en/). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government.
WDFV and STL-E are funded by the National Heart, Lung, And Blood Institute of the National Institutes of Health (www.nhlbi.nih.gov) under Award Number UG3HL156388 and Fogarty International Centre. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We obtained ethical clearance from the University of the Witwatersrand Human Research Ethics Committee (clearance certificate number: M190641). Departmental approval was granted by the Johannesburg Health District (DRC Ref: 2019-10-005 and National Health Research Database reference number: GP_201910_031). Written consent for interviews will be obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding The principal investigator/SBG is funded by the Utrecht University (UU), Department of Interdisciplinary Social Science, Netherlands (https://www.uu.nl/en/organisation/faculty-of-social-and-behavioural-sciences), and by the Carnegie Corporation of New York (https://www.carnegie.org/) (Grant No--B 8606.R02), Sida (https://www.sida.se/en) (Grant No:54100113), the DELTAS Africa Initiative (https://www.aasciences.africa/aesa/programmes/developing-excellence-leadership-training-and-science-africa-deltas-africa#) (Grant No: 107768/Z/15/Z) and Deutscher Akademischer Austauschdienst (DAAD) (https://www.daad.de/en/). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)–s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa–s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (UK) and the UK government.
WDFV and STL-E are funded by the National Heart, Lung, And Blood Institute of the National Institutes of Health (https://www.nhlbi.nih.gov/) under Award Number UG3HL156388 and Fogarty International Centre. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interest The authors declare that they have no competing interests.
Availability of data and materials Materials described in this paper are applicable to the study protocol only and there are no raw data reported. The datasets will be collected and can be made available from the corresponding author on reasonable request. Study codebooks, interview guides, informed consent form, participant information sheet, Systematic Review protocol and PRISMA-P checklist developed for this study protocol are included as supporting information (appendix S1, S2, S3, S4, S5, S6).
Consent for publication Not applicable
Data Availability
Materials described in this paper are applicable to the study protocol only and there are no raw data reported. The datasets will be collected and can be made available from the corresponding author on reasonable request. Study codebooks, interview guides, informed consent form, participant information sheet, Systematic Review protocol and PRISMA-P checklist developed for this study protocol are included as supporting information (appendix S1, S2, S3, S4, S5, S6).
